Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

Overview of attention for article published in Journal of Hematology & Oncology, January 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet

policy: 2 policy sources

Citations

dimensions_citation: 177 Dimensions

Readers on

mendeley: 121 Mendeley

Summary News Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Istodax for Peripheral T-Cell Lymphoma - Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma: Committee papers

Cited by National Institute for Health and Care Excellence on 07 Jun 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.